Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells

Cancer Research

Volumn 59, Issue 6, 1999, Pages 1184-1187

  Murakami, Masaru ^a   Gurski, Karen J ^a   Marincola, Francesco M ^a   Ackland, James ^b   Steller, Michael A ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CSL LIMITED   (Australia)

^c WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS PROTEIN;

ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOLOGY; DENDRITIC CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; UTERINE CERVIX CANCER; WART VIRUS;

ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE SUBSETS; ONCOGENE PROTEINS, VIRAL; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS;

EID: 0033559604     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Bosch, F. X., Manos, M. M., Muñoz, N., Sherman, M., Jansen, A. M., Peto, J., Schiffman, M. H., Moreno, V., Kurman, R., and Shah, K. V. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J. Natl. Cancer Inst., 87: 796-802, 1995.
2. Nasiell, K., Roger, V., and Nasiell, M. Behavior of mild cervical dysplasia during long-term follow-up. Obstet. Gynecol., 67: 665-669, 1986.
3. Shamanin, V., Glover, M., Rausch, C., Proby, C., Leigh, I. M., zur Hausen, H., and de Villiers, E. M. Specific types of human papillomavirus found in benign proliferations and carcinomas of the skin in immunosuppressed patients. Cancer Res., 54: 4610-4613, 1994.
4. Crook, T., Morgenstern, J. P., Crawford, L., and Banks, L. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J., 8: 513-519, 1989.
5. Feltkamp, M. C., Vreugdenhil, G. R., Vierboom, M. P., Ras, E., van der Burg, S. H., ter Schegget, J., Melief, C. J., and Kast, W. M. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur. J. Immunol., 25: 2638-2642, 1995.
6. Steller, M. A., Gurski, K. J., Murakami, M., Daniel, R. W., Shah, K. V., Celis, E., Sette, A., Trimble, E. L., Park, R. C., and Marincola, F. M. Cell-mediated immunologic responses in cervical and vaginal cancer patients with a lipidated epitope of human papillomavirus type 16 E7. Clin. Cancer Res., 4: 2103-2109, 1998.
7. Paglia, P., Chiodoni, C., Rodolfo, M., and Colombo, M. P. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med., 183: 317-322, 1996.
8. Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Kast, W. M., Deleo, A. B., and Lotze, M. T. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med., 1: 1297-1302, 1995.
9. Marincola, F. M., Shamamian, P., Alexander, R. B., Gnarra, J. R., Turetskaya, R. L., Nedospasov, S. A., Simonis, T. B., Taubenberger, J. K., Yannelli, J., and Mixon, A. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J. Immunol., 153: 1225-1237, 1994.
10. Ressing, M. E., Sette, A., Brandt, R. M., Ruppert, J., Wentworth, P. A., Hartman, M., Oseroff, C., Grey, H. M., Melief, C. J., and Kast, W. M. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J. Immunol. 154: 5934-5943, 1995.
11. Sallusto, F., and Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med., 179: 1109-1118, 1994.
12. Inaba, K., Metlay, J. P., Crowley, M. T., and Steinman, R. M. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. [Published erratum appears in J. Exp. Med., 172:1275, 1990]. J. Exp. Med., 172: 631-640, 1990.
13. Lee, T. D. Distribution of HLA antigens in North American Caucasions, North American blacks and orientals. In: J. Lee (ed.), The HLA System: A New Approach, pp. 141-178. New York: Springer-Verlag, 1990.
14. Kim, C. J., Prevette, T., Cormier, J. N., Overwijk, W., Roden, M., Restifo, N. P., Rosenberg, S. A., and Marincola, F. M. Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. J. Immunother., 20: 276-286, 1997.
15. Huang, A. Y., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., and Levitsky, H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (Washington DC), 264: 961-965, 1994.
16. Bachmann, M. F., Lutz, M. B., Layton, G. T., Harris, S. J., Fehr, T., Rescigno, M., and Ricciardi-Castagnoli, P. Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes. Eur. J. Immunol., 26: 2595-2600, 1996.
17. Borysiewicz, L. K., Fiander, A., Nimako, M., Man, S., Wilkinson, G. W., Westmoreland, D., Evans, A. S., Adams, M., Stacey, S. N., Boursnell, M. E., Rutherford, E., Hickling, J. K., and Inglis, S. C. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18. E6 and E7 proteins as immunotherapy for cervical cancer. Lancet, 347: 1523-1527, 1996.
18. Whiteside, T. L., Jost, L. M., and Herberman, R. B. Tumor-infiltrating lymphocytes: potential and limitations to their use for cancer therapy. Crit. Rev. Oncol. Hematol., 12: 25-47, 1992.
19. De Bruijn, M. L., Schuurhuis, D. H., Vierboom, M. P., Vermeulen, H., de Cock, K. A., Ooms, M. E., Ressing, M. E., Toebes, M., Franken, K. L. Drijfhout, J. W., Ottenhoff, T. H., Offringa, R., and Melief, C. J. Immunization with human papillomavirus type 16 (HPV 16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-indueed tumor cells. Cancer Res., 58: 724-731, 1998.
20. Kurman, R. J., Henson, D. E., Herbst, A. L., Noller, K. L., and Schiffman, M. H. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. J. Am. Med. Assoc., 271: 1866-1869, 1994.
21. Lacey, C. J. Assessment of exposure to sexually transmitted agents other than human papillomavirus. In: N. Muñoz. F. X. Bosch, K. V. Shah and A. Meheus (eds.). Epidemiology of Cervical Cancer and Human Papillomavirus, pp. 93-105. Lyon, France: IARC Scientific Publications, 1992.